Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
European Journal of Cancer (Oxford, England : 1990)|July 12, 2011
Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancerGunter von Minckwitz, Kathrin Schwedler, Marcus Schmidt, et al.
Cancers|October 1, 2020
Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain MetastasesElena Laakmann, Isabell Witzel, Tanja Neunhöffer, et al.
Anti-Cancer Drugs|March 16, 2019
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)Joachim Bischoff, Jana Barinoff, Christoph Mundhenke, et al.
BMC Medicine|October 8, 2024
Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancerPhilipp Zimmer, Tobias Esser, Diana Lueftner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2019
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)Ingrid A Mayer, Aleix Prat, Daniel Egle, et al.
Breast (Edinburgh, Scotland)|April 5, 2025
Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBCElena Laakmann, Marcus Schmidt, Kristina Lübbe, et al.
Cancers|October 21, 2020
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with PertuzumabLaura L Michel, Andreas D Hartkopf, Peter A Fasching, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT RegistryAndreas D Hartkopf, Christina B Walter, Hans-Christian Kolberg, et al.
BMC Cancer|October 16, 2024
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtypePhilipp Ziegler, Andreas D Hartkopf, Markus Wallwiener, et al.
Breast (Edinburgh, Scotland)|February 14, 2025
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancerChristina B Walter, Andreas D Hartkopf, Alexander Hein, et al.
Pageof 9